^
Association details:
Biomarker:HER-2 positive
Cancer:HER2 Positive Breast Cancer
Regimen:TC (cyclophosphamide + docetaxel)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

P012 Survival outcomes and toxicities of adjuvant docetaxelcyclophosphamide for four cycles in node negative triple negative and HER2 positive Chinese breast cancer patients: A 10 year follow up study

Published date:
03/16/2023
Excerpt:
DC4 resulted in excellent survival outcomes for nodenegative TNBC and HER2+ BC, which were comparable to historical cohorts using more intensive regimens in the literature.